Genetics of myeloid leukemias

Annual Review of Genomics and Human Genetics

Volumn 3, Issue , 2002, Pages 179-198

  Kelly, Louise M ^a   Gilliland, D Gary ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Chromosomal translocations; Hematopoiesis; Hematopoietic transcription factors; Myelodysplastic syndrome; Tyrosine kinases

Indexed keywords

BCR ABL PROTEIN; FLT3 LIGAND; IMATINIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR; TRANSCRIPTION FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER SURVIVAL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; COMPETITIVE INHIBITION; ENZYME ACTIVATION; GENE MUTATION; GENE THERAPY; HEMATOPOIESIS; HUMAN; INHIBITION KINETICS; MOLECULAR CLONING; NONHUMAN; ONCOGENE K RAS; ONCOGENE N RAS; PHENOTYPE; POINT MUTATION; REVIEW; STEM CELL;

CELL DIFFERENTIATION; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID; MODELS, BIOLOGICAL; MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; TRANSLOCATION, GENETIC;

EID: 0036406845     PISSN: 15278204     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.genom.3.032802.115046     Document Type: Review

References (106)

1. Abu-Duhier F, Goodeve A, Wilson G, Gari M, Peake I, et al. 2000. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br. J. Haematol. 111:190-95
2. Abu-Duhier FM, Goodeve AC, Wilson GA, Care RS, Peake IR, Reilly JT. 2001. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br. J. Haematol. 113:983-88
3. Ahuja HG, Popplewell L, Tcheurekdjian L, Slovak ML. 2001. NUP98 gene rearrangements and the clonal evolution of chronic myelogenous leukemia. Genes Chromosomes Cancer 30:410-15
4. Amann JM, Nip J, Strom DK, Lutterbach B, Harada H, et al. 2001. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds msin3a through its oligomerization domain. Mol. Cell. Biol. 21:6470-83
5. Beaupre DM, Kurzrock R. 1999. RAS and leukemia: From basic mechanisms to gene-directed therapy. J. Clin. Oncol. 17:1071-79
6. Binns KL, Taylor PP, Sicheri F, Pawson T, Holland SJ. 2000. Phosphorylation of tyrosine residues in the kinase domain and juxtamembrane region regulates the biological and catalytic activities of Eph receptors. Mol. Cell. Biol. 20:4791-805
7. Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, et al. 1997. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 90:4947-52
8. Palmer AM, Mahajan S, Frank D, Druker BJ, et al. 2000. The TEL/PDGFβR fusion protein activates STAT 1 and 5: A common mechanism for transformation by tyrosine kinase fusion proteins. Exp. Hematol. 28:584-93
9. Castilla LH, Garrett L, Adya N, Orlic D, Dutra A, et al. 1999. The fusion gene CbfB blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukemia. Nat. Genet. 23:144-46
10. Castilla LH, Wijmenga C, Wang Q, Stacy T, Speck NA, et al. 1996. Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11. Cell 87:687-96
11. Costoya JA, Pandolfi PP. 2001. The role of promyelocytic zinc finger and promyelocytic leukemia in leukemogenesis and development. Curr. Opin. Hematol. 8:212-17
12. Cuenco GM, Nucifora G, Ren R. 2000. Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: A model for human AML. Proc. Natl. Acad. Sci. USA 97:1760-65
13. Dash A, Gilliland DG. 2001. Molecular genetics of acute myeloid leukaemia. Best Pract. Res. Clin. Haematol. 14:49-64
14. Druker B. 2001. Signal transduction inhibition: Results from phase I clinical trials in chronic myeloid leukemia. Semin. Hematol. 38:9-14
15. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, et al. 2001. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344:1038-42
16. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, et al. 2001. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344:1031-37
17. Erickson P, Gao J, Chang KS, Look T, Whisenant E, et al. 1992. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood 80:1825-31
18. Fenaux P. 2001. Chromosome and molecular abnormalities in myelodysplastic syndromes. Int. J. Hematol. 73:429-37
19. Fenrick R, Amann JM, Lutterbach B, Wang L, Westendorf JJ, et al. 1999. Both TEL and AML-1 contribute repression domains to the t(12;21) fusion protein. Mol. Cell. Biol. 19:6566-74
20. Fenski R, Flesch K, Serve S, Mizuki M, Oelmann E, et al. 2000. Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells. Br. J. Haematol. 108:322-30
21. Ford AM, Bennett CA, Price CM, Bruin MC, Van Wering ER, Greaves MF. 1998. Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia. Proc. Natl. Acad. Sci. USA 95:4584-88
22. Frank R, Zhang J, Uchida H, Meyers S, Hiebert SW, Nimer SD. 1995. The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B. Oncogene 11:2667-74
23. Frohling S, Breitruck J, Schlenk R, Kreitmeier S, Tobis K, et al. 2001. FLT3 internal tandem duplications and survival in adult acute myeloid leukemia: Analysis of 188 intensively treated patients. Blood 89:717a
24. Gelmetti V, Zhang J, Fanelli M, Minucci S, Pelicci PG, Lazar MA. 1998. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia partner ETO. Mol. Cell. Biol. 18:7185-91
25. Gilliland DG. 2001. Hematologic malignancies. Curr. Opin. Hematol. 8:189-91
26. Golub TR, Barker GF, Bohlander SK, Hiebert SW, Ward DC, et al. 1995. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. USA 92:4917-21
27. Golub TR, Barker GF, Lovett M, Gilliland DG. 1994. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77:307-16
28. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, et al. 2001. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876-80
29. Griffin JD. 2001. Point mutations in the FLT3 gene in AML. Blood 97:2193A
30. Grisolano JL, Wesselschmidt RL, Pelicci PG, Ley TJ. 1997. Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences. Blood 89:376-87
31. Hayakawa F, Towatari M, Kiyoi H, Tanimoto M, Kitamura T, et al. 2000. Tandem-duplicated FLT3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 19:624-31
32. He LZ, Tolentino T, Grayson P, Zhong S, Warrell RP Jr, et al. 2001. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J. Clin. Invest. 108:1321-30
33. Hiebert SW, Sun W, Davis JN, Golub TR, Shurtleff S, et al. 1996. The t(12;21) converts AML-1B from an activator to a repressor of transcription. Mol. Cell. Biol. 16:1349-55
34. Higuchi M, O'Brien D, Kumaravelu P, Lenny N, Yeoh E-J, Downing JR. 2002. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell 1:63-74
35. Horiike S, Yokota S, Nakao M, Iwai T, Sasai Y, et al. 1997. Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia. Leukemia 11:1442-46
36. Imai Y, Kurokawa M, Izutsu K, Hangaishi A, Takeuchi K, et al. 2000. Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis. Blood 96:3154-60
37. Ishii E, Zaitsu M, Ihara K, Hara T, Miyazaki S. 1999. High expression but no internal tandem duplication of FLT3 in normal hematopoietic cells. Pediatr. Hematol. Oncol. 16:437-41
38. Iwai T, Yokota S, Nakao M, Kaneko H, Nakai H, et al. 1997. Internal tandem duplication in the juxtatransmembrane domain of the FLT3 is not involved in blastic crisis of chronic myeloid leukemia. Leukemia 11:1992-93
39. Iwai T, Yokota S, Nakao M, Okamoto T, Taniwaki M, et al. 1999. Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia. The Children's Cancer and Leukemia Study Group, Japan. Leukemia 13:38-43
40. Jamal R, Taketani T, Taki T, Bessho F, Hongo T, et al. 2001. Coduplication of the MLL and FLT3 genes in patients with acute myeloid leukemia. Genes Chromosomes Cancer 31:187-90
41. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, et al. 2001. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 344:1052-56
42. Karp JE. 2001. Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies. Semin. Hematol. 38:16-23
43. Kelly LM, Liu Q, Kutok JL, Williams IR, Boulton CL, Gilliland DG. 2002. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood 99:310-18
44. Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, et al. 1999. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 93:3074-80
45. Kiyoi H, Naoe T, Yokota S, Nakao M, Minami S, et al. 1997. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia 11:1447-52
46. Kiyoi H, Towatari M, Yokota S, Hamaguchi M, Ohno R, et al. 1998. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 12:1333-37
47. Kondo M, Horibe K, Takahashi Y, Matsumoto K, Fukuda M, et al. 1999. Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia. Med. Pediatr. Oncol. 33:525-29
48. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, et al. 2001. The presence of a FLT3 internal tandem duplications in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk greoup and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98:1752-59
49. Deleted in proof
50. Kozu T, Miyoshi H, Shimizu K, Maseki N, Kaneko Y, et al. 1993. Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction. Blood 82:1270-76
51. Levis M, Tse KF, Smith BD, Garrett E, Small D. 2001. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood 98:885-87
52. Levis MJ, Allebach J, Tse KF, Zheng R, Baldwin BR, et al. 2001. FLT3-targeted inhibitors kill FLT3-dependent modeled cells, leukemia-derived cell lines, and primary AML blasts in vitro and in vivo. Blood 89:721a
53. Liu P, Tarle SA, Hajra A, Claxton DF, Marlton P, et al. 1993. Fusion between transcription factor CBFB/PEBP2B and a myosin heavy chain in acute myeloid leukemia. Science 261:1041-44
54. Lutterbach B, Hou Y, Durst KL, Hiebert SW. 1999. The inv(16) encodes an acute myeloid leukemia 1 transcriptional core-pressor. Proc. Natl. Acad. Sci. USA 96:12822-27
55. Lutterbach B, Westendorf JJ, Linggi B, Isaac S, Seto E, Hiebert SW. 2000. A mechanism of repression by acute myeloid leukemia-1, the target of multiple chromosomal translocations in acute leukemia. J. Biol. Chem. 275:651-56
56. Lutterbach B, Westendorf JJ, Linggi B, Patten A, Moniwa M, et al. 1998. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol. Cell. Biol. 18:7176-84
57. Melnick A, Carlile GW, McConnell MJ, Polinger A, Hiebert SW, Licht JD. 2000. AML-1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc-finger protein. Blood 96:3939-47
58. Melnick AM, Westendorf JJ, Polinger A, Carlile GW, Arai S, et al. 2000. The ETO protein disrupted in t(8;21)-associated acute myeloid leukemia is a corepressor for the promyelocytic leukemia zinc finger protein. Mol. Cell. Biol. 20:2075-86
59. Meshinchi S, Woods WG, Stirewalt DL, Sweetser DA, Buckley JD, et al. 2001. Prevalence and prognostic significance of FLT3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 97:89-94
60. Meyers S, Lenny N, Hiebert SW. 1995. The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation. Mol. Cell. Biol. 15:1974-82
61. Michaud J, Wu F, Osato M, Cottles GM, Yanagida M, et al. 2002. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: Implications for mechanisms of pathogenesis. Blood 99:1364-72
62. Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, et al. 2000. FLT3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 96:3907-14
63. Nakano Y, Kiyoi H, Miyawaki S, Asou N, Ohno R, et al. 1999. Molecular evolution of acute myeloid leukaemia in relapse: Unstable N-ras and FLT3 genes compared with p53 gene. Br. J. Haematol. 104:659-64
64. Nakao M, Janssen J, Erz D, Seriu T, Bartram C. 2000. Tandem duplication of the FLT3 gene in acute lymphoblastic leukemia, a marker for the monitoring of minimal residual disease. Leukemia 14:522-24
65. Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, et al. 1996. Internal tandem duplication of the FLT3 gene found in acute myeloid leukemia. Leukemia 10:1911-18
66. Naoe T, Kiyoe H, Yamamoto Y, Minami Y, Yamamoto K, et al. 2001. FLT3 tyrosine kinase as a target molecule for selective antileukemia therapy. Cancer Chemother. Pharmacol. 48:S27-30
67. Neubauer A, Dodge RK, George SL, Davey FR, Silver RT, et al. 1994. Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood 83:1603-11
68. Neubauer A, Greenberg P, Negrin R, Ginzton N, Liu E. 1994. Mutations in the ras proto-oncogenes in patients with myelodysplastic syndromes. Leukemia 8:638-41
69. Nomdedeu JF, Brunet S, Colomer D, Estivill C, Llorente J, et al. 2001. D835 mutations are commonly associated with other molecular lesions in adult AML. Blood 89:579a
70. Okuda T, Cai Z, Yang S, Lenny N, Lyu CJ, et al. 1998. Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood 91:3134-43
71. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. 1996. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84:321-30
72. Osato M, Asou N, Abdalla E, Hoshino K, Yamasaki H, et al. 1999. Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias. Blood 93:1817-24
73. Pabst T, Mueller BU, Harakawa N, Schoch C, Haferlach T, et al. 2001. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat. Med. 7:444-51
74. Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, et al. 2001. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat. Genet. 27:263-70
75. Pandolfi PP. 2001. Histone deacetylases and transcriptional therapy with their inhibitors. Cancer Chemother. Pharmacol. 48:S17-19
76. Peters DG, Hoover RR, Gerlach MJ, Koh EY, Zhang H, et al. 2001. Activity of the famesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood 97:1404-12
77. Pollock JL, Westervelt P, Kurichety AK, Pelicci PG, Grisolano JL, Ley TJ. 1999. A bcr-3 isoform of RARalpha-PML potentiates the developmnet of PML/RARα driven acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA 96:15103-8
78. Pollock JL, Westervelt P, Walter MJ, Lane AA, Ley TJ. 2001. Mouse models of acute promyelocytic leukemia. Curr. Opin. Hematol. 8:206-11
79. Preudhomme C, Warot-Loze D, Roumier C, Grardel-Duflos N, Garand R, et al. 2000. High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. Blood 96:2862-69
80. Romana SP, Mauchauffe M, Leconiat M, Chumakov I, Le Paslier D, et al. 1995. The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion. Blood 85:3662-70
81. Rombouts WJ, Blokland I, Lowenberg B, Ploemacher RE. 2000. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the FLT3 gene. Leukemia 14:675-83
82. Schwaller J, Parganas E, Wang D, Cain D, Aster JC, et al. 2000. Stat5a/b is essential for the myelo- and lymphoproliferative disease indcued by TEL/JAK2. Mol. Cell 6:693-704
83. Sebti S, Hamilton AD. 1997. Inhibitors of prenyl transferases. Curr. Opin. Oncol. 9:557-61
84. Sexl V, Piekorz R, Moriggl R, Rohrer J, Brown MP, et al. 2000. Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of stat5. Blood 96:2277-83
85. Song W-J, Sullivan MG, Legare RD, Hutchings S, Tan X, et al. 1999. Haploin-sufficiency of CBFA2(AML1) causes familial thrombocytopenia with propensity to develop acute myelogenous leukemia (FPD/AML). Nat. Genet. 23:166-75
86. Speck NA, Stacy T, Wang Q, North T, Gu TL, et al. 1999. Core-binding factor: A central player in hematopoiesis and leukemia. Cancer Res. 59 (Suppl.):1789-93
87. Stirewalt DL, Kopecky KJ, Meshinchi S, Appelbaum FR, Slovak ML, et al. 2001. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 97:3589-95
88. Theising J, Ohno-Jones S, Kolibaba K, Druker B. 2000. Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl-positive cells. Blood 96:3195-99
89. Thiede C, Steudel C, Mohr B, Schaich M, Schaekel U, et al. 2001. Analysis of FLT3-activating mutations in 713 patients with acute myelogenous leukemia (AML): High prevalence in FAB-subtype M5 and identification of subgroups with poor prognosis. Blood 89:717a
90. Tomasson MH, Williams IR, Hasserjian R, Udomsakdi C, McGrath SM, et al. 1999. TEL/PDGFβR induces hematologic malignancy in mice that responds to the tyrosine kinase inhibitor CGP57148. Blood 93:1707-14
91. Tse KF, Novelli E, Civin CI, Bohmer FD, Small D. 2001. Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor. Leukemia 15:1001-10
92. Wang L, Hiebert SW. 2001. TEL contacts multiple co-repressors and specifically associates with histone deacetylase-3. Oncogene 20:3716-25
93. Wang Q, Stacy T, Binder M, Marin-Padilla M, Sharpe AH, Speck NA. 1996. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc. Natl. Acad. Sci. USA 93:3444-49
94. Weiss A, Schlessinger J. 1998. Switching signals on or off by receptor dimerization. Cell 94:277-80
95. Westendorf JJ, Yamamoto CM, Lenny N, Downing JR, Selsted ME, Hiebert SW. 1998. The t(8;21) fusion product, AML-1-ETO, associates with C/EBP-alpha, inhibits C/EBP-alpha-dependent transcription and blocks granulocytic differentiation. Mol. Cell. Biol. 18:322-33
96. Whitman SP, Archer KJ, Feng L, Baldus C, Becknell B, et al. 2001. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: A cancer and leukemia group B study. Cancer Res. 61:7233-39
97. Wiemels JL, Cazzaniga G, Daniotti M, Eden OB, Addison GM, et al. 1999. Prenatal origin of acute lymphoblastic leukaemia in children. Lancet 354:1499-503
98. Wybenga-Groot LE, Baskin B, Ong SH, Tong J, Pawson T, Sicheri F. 2001. Structural basis for autoinhibition of the Ephb2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region. Cell 106:745-57
99. Xu F, Taki T, Eguchi M, Kamada N, Ishii E, et al. 2000. Tandem duplication of the FLT3 gene is infrequent in infant acute leukemia. Japan Infant Leukemia Study Group. Leukemia 14:945-47
100. Xu F, Taki T, Yang H, Hanada R, Hongo T, et al. 1999. Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children. Br. J. Haematol. 105:155-62
101. Deleted in proof
102. Yamamoto K, Nakamura Y, Saito K, Furusawa S. 2000. Expression of the NUP98/HOXA9 fusion transcript in the blast crisis of Philadelphia chromosome positive CML with t(7;11)(p15;p15). Br. J. Haematol. 109:423-26
103. Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, et al. 2001. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97:2434-39
104. Yergeau DA, Hetherington CJ, Wang Q, Zhang P, Sharpe AH, et al. 1997. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat. Genet. 15:303-6
105. Yokota S, Kiyoi H, Nakao M, Iwai T, Misawa S, et al. 1997. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 11:1605-9
106. Zimonjic DB, Pollock JL, Westervelt P, Popescu NC, Ley TJ. 2000. Acquired, nonrandom chromosomal abnormalities associated with the development of acute promyelocytic leukemia in transgenic mice. Proc. Natl. Acad. Sci. USA 97:13306-11